• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Social Capital Suvretta Holdings Corp. I (Amendment)

    8/23/22 5:08:11 PM ET
    $DNAA
    Get the next $DNAA alert in real time by email
    SC 13G/A 1 tm2224332d2_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    (Amendment No. 1 – Exit Filing)*
    Under the Securities Exchange Act of 1934

     

     

     

    Akili, Inc.
    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share
    (Titles of Class of Securities)

     

    00974B107
    (CUSIP Number)

     

    August 19, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1 NAME OF REPORTING PERSON
    SCS Sponsor I LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ¨ (b) ¨
    3

    SEC USE ONLY

    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Cayman Islands
    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%
    12 TYPE OF REPORTING PERSON
    OO

     

    -2-

     

     

    1 NAME OF REPORTING PERSON
    SC SPAC Holdings LLC
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ¨ (b) ¨
    3

    SEC USE ONLY

    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%
    12 TYPE OF REPORTING PERSON
    OO

     

    -3-

     

     

    1 NAME OF REPORTING PERSON
    Kishan Mehta
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ¨ (b) ¨
    3

    SEC USE ONLY

    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%
    12 TYPE OF REPORTING PERSON
    IN

     

    -4-

     

     

    1 NAME OF REPORTING PERSON
    Aaron Cowen
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ¨ (b) ¨
    3

    SEC USE ONLY

    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    United States
    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5 SOLE VOTING POWER
    0
    6 SHARED VOTING POWER
    0
    7 SOLE DISPOSITIVE POWER
    0
    8 SHARED DISPOSITIVE POWER
    0

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨

     

    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
    0%
    12 TYPE OF REPORTING PERSON
    IN

     

    -5-

     

     

    Explanatory Note:

     

    This Amendment No. 1 (this “Amendment”) amends, in its entirety, with respect to the Reporting Persons only, the statement on Schedule 13G filed on February 9, 2022 (the “Initial 13G”) by the Reporting Persons (as defined below) and Chamath Palihapitiya. On August 19, 2022, the SPAC (as defined below) consummated the business combination (the “Business Combination”) contemplated by that certain Agreement and Plan of Merger, dated as of January 26, 2022 (the “Merger Agreement”), by and among the SPAC, Karibu Merger Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of the SPAC (“Merger Sub”), and Akili Interactive Labs, Inc., a Delaware corporation. Concurrently with the consummation of the Business Combination, SCS Sponsor I (as defined below) distributed for no consideration 6,860,000 shares of Issuer Common Stock (as defined below) to its members pro rata in accordance with their respective interests (the “Distribution”), such that following the Distribution, SCS Sponsor I ceased to be the record holder of such shares, and consequently, the Reporting Persons ceased to beneficially own such shares by virtue of their direct or indirect interests in SCS Sponsor I. This Amendment is being filed to disclose that the Reporting Persons have ceased to be the beneficial owner of more than five percent of any class of equity security (as defined in Rule 13d-1(i)) of the Issuer (as defined below) as a result of their direct or indirect interests in SCS Sponsor I. This Amendment is the final amendment to the Initial 13G and constitutes an exit filing for each of the Reporting Persons in respect of the Initial 13G. However, this Amendment shall not constitute an amendment to the Initial 13G or an exit filing for Mr. Palihapitiya. Concurrently with the filing of this Amendment, Aaron Cowen, together with the other reporting persons named therein, are filing a statement on Schedule 13G to reflect the beneficial ownership of the shares of Issuer Common Stock following the Distribution, together with the other shares of Issuer Common Stock that may be deemed to be beneficially owned by the reporting persons named therein as of the date of the filing of such Schedule 13G.

     

    Item 1(a).Name of Issuer:

     

    Akili, Inc. (formerly known as Social Capital Suvretta Holdings Corp. I), a Delaware corporation (the “Issuer” and, prior to the consummation of the Business Combination, the “SPAC”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    125 Broad Street, Fifth Floor, Boston, Massachusetts 02110

     

    Item 2(a).Name of Person Filing:

     

    This statement is being filed jointly pursuant to §240.13d-1(k)(1) on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    1.SCS Sponsor I LLC (“SCS Sponsor I”)

     

    2.SC SPAC Holdings LLC (the successor by merger to ChaChaCha DNA I, LLC)

     

    3.Kishan Mehta

     

    4.Aaron Cowen

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The principal business address of each of the Reporting Persons is as follows:

     

    c/o SCS Sponsor I LLC, 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV 89052

     

    Item 2(c).Citizenship:

     

    See responses to Item 4 on each cover page.

     

    -6-

     

     

    Item 2(d).Titles of Classes of Securities:

     

    Common stock, par value $0.0001 per share (“Issuer Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    The shares of Issuer Common Stock CUSIP Number is 00974B107.

     

    Item 3.If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

     

    (c) ¨Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

     

    (d) ¨Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e) ¨Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) ¨Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).

     

    (h)  ¨Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     

    (k) ¨ Group in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________ .

     

    Item 4.Ownership

     

    (a)       Amount beneficially owned:

     

    See responses to Item 9 on each cover page.

     

    (b)       Percent of class:

     

    See responses to Item 11 on each cover page.

     

    (c)       Number of shares as to which such person has:

     

    (i)       Sole power to vote or to direct the vote:

     

    See responses to Item 5 on each cover page.

     

    (ii)       Shared power to vote or to direct the vote:

     

    See responses to Item 6 on each cover page.

     

    -7-

     

     

    (iii)       Sole power to dispose or to direct the disposition of:

     

    See responses to Item 7 on each cover page.

     

    (iv)       Shared power to dispose or to direct the disposition of:

     

    See responses to Item 8 on each cover page.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    None.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certification.

     

    Not Applicable.

     

    -8-

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 23, 2022

     

      SCS Sponsor I LLC

     

    By:/s/ Chamath Palihapitiya
      Name: Chamath Palihapitiya
      Title: Chief Executive Officer

     

     

      SC SPAC Holdings LLC
      By: SC Master Holdings, LLC, its sole member
      By: Social Capital Group LLC, its sole member

     

    By:/s/ Chamath Palihapitiya
      Name: Chamath Palihapitiya
      Title: Chief Executive Officer

     

      /s/ Kishan Mehta
      Kishan Mehta
       
      /s/ Aaron Cowen
      Aaron Cowen

     

    -9-

    Get the next $DNAA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      1/20/23 6:27:44 AM ET
      $DNAA
    • SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. I

      SC 13D - Akili, Inc. (0001850266) (Subject)

      8/30/22 4:48:09 PM ET
      $DNAA
    • SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. I

      SC 13G - Akili, Inc. (0001850266) (Subject)

      8/29/22 12:28:20 PM ET
      $DNAA

    $DNAA
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where

      3/17/22 9:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer

      Jon David brings deep expertise in building and launching engaging products to the Akili leadership team Akili Interactive ("Akili" or the "Company"), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer. In his role, David will be responsible for developing and executing the strategic vision of Akili's future product pipeline as the company continues to lead the way in establishing an entirely new category of medicine - one where the treatment is experienced like high-end entertainment. Reporting to the CEO, David will join the Akili executive team, which includes leader

      3/17/22 9:00:00 AM ET
      $DNAA

    $DNAA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PureTech Health plc – Half-Year Report

      Strong capital base with PureTech Level Cash and Cash Equivalents of $341.4 million1 and Consolidated Cash and Cash Equivalents of $365.9 million2 as of June 30, 2022, excluding up to $115.4 million added post-period3; Operational runway extended into Q1 2026 Significant advancement of PureTech's Wholly Owned Programs, with three clinical trials underway, four completed, and human proof-of-principle achieved for a key PureTech platform Excellent progress across the Founded Entities, including Karuna's positive topline Phase 3 results for KarXT in schizophrenia, Akili's Nasdaq listing and Gelesis' commercial progress with Plenity®4 in the post-period, and four clinical data publications ac

      8/25/22 2:07:00 AM ET
      $CPSR
      $DNAA
      $GLS
      $KRTX
      Business Services
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Digital Medicine Leader Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

      Akili, Inc. common stock to begin trading on Nasdaq under the ticker symbol "AKLI" on August 22, 2022 Total gross proceeds of more than $163 million will support launch of first FDA-cleared video game treatment and advancement of late-stage pipeline Akili, a leading digital medicine company, today completed its previously announced business combination with Social Capital Suvretta Holdings Corp. I ("SCS") (NASDAQ:DNAA), a publicly traded special purpose acquisition company. The newly formed company, Akili, Inc. ("Akili"), is expected to start trading on The Nasdaq Capital Market ("Nasdaq") under the new ticker symbol "AKLI" on August 22, 2022. Akili raised more than $163 million from the

      8/19/22 5:25:00 PM ET
      $DNAA
    • PureTech Founded Entity Akili Announces Public Company Board of Director Nominees

      New and recent director nominees include industry trailblazers BJ Jones of Biohaven Pharmaceuticals; Christine Lemke of Evidation Health; Ken Ehlert, formerly of UnitedHealth Group; and Chamath Palihapitiya of Social Capital and SCS PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, today announced the nominees for its future board of directors, effective upon the closing of Akili's business combination with Social Capital Suvretta H

      7/11/22 7:05:00 AM ET
      $DNAA
      $PRTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Jina Anil (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:14:59 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Ehlert Kenneth (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:15:13 PM ET
      $DNAA
    • SEC Form 3 filed by new insider Martucci Walter Edward Ii (Amendment)

      3/A - Akili, Inc. (0001850266) (Issuer)

      12/13/22 8:10:52 PM ET
      $DNAA

    $DNAA
    SEC Filings

    See more
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:13:45 AM ET
      $DNAA
    • Social Capital Suvretta Holdings Corp. I filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Akili, Inc. (0001850266) (Filer)

      1/12/23 8:06:32 AM ET
      $DNAA
    • SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. I

      424B3 - Akili, Inc. (0001850266) (Filer)

      1/5/23 7:21:42 AM ET
      $DNAA

    $DNAA
    Financials

    Live finance-specific insights

    See more
    • PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      In addition to PureTech's advanced Wholly Owned Pipeline, Founded Entities are an additional source of value and Akili is now set to join the growing list of publicly-traded Founded Entities for PureTech, which also include Karuna Therapeutics (NASDAQ:KRTX), Vor Biopharma (NASDAQ:VOR) and Gelesis (NYSE:GLS) Fully committed PIPE of $162 million led by $100 million from Social Capital with remaining $62 million from new and existing investors including: Suvretta Capital Management's Averill strategy, Apeiron Investment Group, Temasek, co-founder PureTech Health, Polaris Partners, Evidity Health Capital, JAZZ Venture Partners and Omidyar Technology Ventures Transaction values the combined co

      1/26/22 7:02:00 AM ET
      $DNAA
      $GLS
      $KRTX
      $PRTC
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I

      Akili's leading digital therapeutic platform combines science and technology to address cognitive impairments in patients, reimagining how central nervous system medicines are designed, developed, and delivered Transaction will support commercial launch of EndeavorRx®, a first-of-its-kind, FDA-cleared and CE-marked prescription digital therapeutic for pediatric ADHD, as well as advance clinical development pipeline across multiple neuropsychiatric diseases, including expanded ADHD populations, multiple sclerosis, autism, and depression Transaction values the combined company at an equity value post-money of up to approximately $1 billion and is expected to provide up to $412 million in

      1/26/22 7:00:00 AM ET
      $DNAA